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Abstract
Background Probabilistic decision analysis is a means of
reflecting the uncertainty parameter in models and of pre-
senting it in a comprehensible manner to decision-makers.
Materials and methods A cost-effectiveness model was
constructed to compare the cementless and cemented total
hip prostheses implanted at our department in terms of
lifetime costs and quality-adjusted life-years (QALY). Re-
vision rates were obtained from the Orthopaedic Prosthe-
sis Register of the Laboratory of Medical Technology,
Istituti Ortopedici Rizzoli, Bologna, Italy.
Results The risk of early revision (at 5 years of follow-up)
for cementless and cemented prostheses was 1.6% and
1.4%, respectively, resulting in equal QALYfor the two im-
plant types. Analysis of mean cost and QALYindicated that
use of either implant is not associated with cost savings.
Discussion. Management with cementless or cemented
total hip prostheses in a theoretical cohort of 70-year-old
patients with fracture of the femoral neck or arthritis
involving the hip is not significantly different according
to the probabilistic results from the model.
Keywords Cost-effectiveness analysis · Total hip
arthroplasty
Introduction
Excellent long-term clinical and radiographic outcomes
have been reported for total hip arthroplasty (THA) using
traditional cementless and cemented prostheses [1, 2].
Hip prosthesis technology is continually evolving, with
new designs and fixation methods being proposed and
introduced [3]. Orthopaedic innovation in THA technolo-
gy has been referred to as a “trial and error culture” [3].
In Italy, where over 150 different implant models are used,
there is no nationally coordinated monitoring of new THA
devices and their use [4]. A growing number of prostheses
is available, with little or no scientific evidence that the
newer implants are any better than the established ones [5].
Randomized controlled trials are the gold standard for
demonstrating the clinical benefits of new technologies.
However, detecting small differences in failure rates
among implants requires randomizing large numbers of
patients and following them for extended periods (15–20
years, or longer). These studies are difficult to perform
due to practical considerations of time and cost. In con-
trast, decision-analysis techniques offer the potential to
analyze the performance of a new technology prior to the
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Furthermore, the results from a well-designed decision
analysis study can guide further clinical and laboratory
research based on the variables that have the greatest
influence on cost-effectiveness. Finally, a cost effective-
ness framework can also be readily updated as new infor-
mation on cost-and clinical effectiveness emerges from
randomized trials and cohort studies [6].
The primary objectives of this study were to establish
a framework within which to evaluate the cost-effective-
ness of cementless and cemented implants and to analyze
how device cost and revision rates affect the model.
Patients and methods
A Markov decision model was used to analyze a theoreti-
cal cohort of 70-year-old patients with unsuccessful man-
agement of femoral neck fracture or arthritis involving the
hip [7]. Seventy years is the average age of THA recipi-
ents according to the report of the Regional Orthopaedic
Prosthesis (RIPO) register of the Laboratory of Medical
Technology, Istituti Ortopedici Rizzoli, Bologna. The
clinical scenario modelled in the study is shown in Fig. 1. 
Outcomes and utilities were measured as quality-
adjusted life-years (QALY), and costs were measured in
2006 euros from the database of our institution. All costs
and outcomes incurred after time zero were discounted at
a yearly rate of 3% for consistency with current cost-
effectiveness analysis practices in medicine [8]. The
model (Fig. 2) was constructed using a decision-analysis
software (TreeAge Pro 2004; TreeAge Software,
Williamstown, USA).
The following general assumptions were made in
model construction [9]: patients with successful cement-
ed or cementless implants the same utility, or QALY
value, after the initial postoperative period; the mortality
rates of patients who survived THAdo not differ from the
age-adjusted mortality rates of patients who did not
undergo THA; revision of either a cemented or a cement-
less device is by total replacement and has the same cost
and functional outcomes; and, patients undergo a single
revision and remain in the “well with revision” state until
death. The specific parameter values used in the decision
model are shown in Table 1.
Data from the RIPO register, recording 23966 THAs,
were used to estimate the probability of revision of
cemented and cementless implants [10]. The probability
of infection after implantation of a total cemented or
cementless prosthesis was set at 0.044% for the base case
[11]. All patients who had an infection were presumed to
have had a revision procedure.
The age-specific probability of death from causes
unrelated to THA was made equal to the probability of
death at each specific age, as determined from the 2001
United States Life Tables [12]. The probability of periop-
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Fig. 1 The clinical scenario modelled in
the study
Table 1 Model parameters used for the base case
Parameters Cementless THA Cemented THA Revision hip arthroplasty
Literature-derived parameters
Infection (%) 0.044 0.044 -
Peri-operative death (%) 0.34 0.34 1.2
Utilities and postoperative tolls 0.92 0.92 0.80
Revision rate 1.6 1.4 NA
Costs
Common terminology code 81.51 81.51 81.53
Mean implant cost (€) 3206.44 1146.00 3249.75
THA total hip arthroplsty, NA not applicable
Cemented THA
Revision Well with revision
Well with cemented THA
Well with cemented THA
Death
Cementless THA
Peri-operative
deatherative death for patients undergoing THA was estimated
from the study of Chang and co-workers [11], who calcu-
lated rates of 0.34% for primary THA and of 1.2% for
revision THA. In this study, the probability of periopera-
tive death after a primary cemented THA was assumed to
be the same as after cementless THA for the base case.
The utilities used in the model were based on quality
well-being index scores [13] reported in the literature
[11]. A longitudinal cohort study of 1356 patients demon-
strated quality well-being index scores of 0.92 in arthritis
patients aged 75–84 years and of 0.80 after revision sur-
gery compared with 0.71 in patients without arthritis in
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Fig. 2 The model constructed with use of decision-analysis software (TreeAge Pro 2004; TreeAge Software, Williamstown, USA)
Treatment option
Cementless THA
Cement THA
Dead
Septic Revision
Revision
Well (post procedure)
Dead
Septic Revision
Revision
Well (post procedure)
Survive
Well
Die, other
Dead
Dead
Dead
Septic revision
Dead
Survive
Dead
Survive
Revision
Survive
Die, other
Dead
Dead
Dead
Septic revision
Dead
Survive
Dead
Survive
Revision
Septic
Septic
Well
Survive
Septic revision
Dead
Survive
Die
Revision
Dead
Well (post procedure)
Septic revision
Dead
Survive
Die
Revision
Dead
Well (post procedure)
Die
Aseptic
Well
Survive
Die
Aseptic
Well
---Markov Inform…
Term:
---Markov Inform…
Term:
---Markov Information
Init Rwd:0
Incr Rwd:0
Final Rwd: 0
---Markov Information
Init Rwd:0
Incr Rwd:0
Final Rwd: 0
---Markov Information
Init Rwd:0
Incr Rwd:0
Final Rwd: 0
---Markov Information
Init Rwd:0
Incr Rwd:0
Final Rwd: 0
---Markov Information
Init Rwd:0
Incr Rwd:0
Final Rwd: 0
---Markov Information
Init Rwd:0
Incr Rwd:0
Final Rwd: 0
---Markov Information
Init Rwd:0
Incr Rwd:0
Final Rwd: 0
---Markov Information
Init Rwd:0
Incr Rwd:0
Final Rwd: 0the same age group [14]. The final utility values used for
the base case in the model are shown in Table 1.
The costs of cementless and cemented THA were esti-
mated from a payer perspective using average hospital
costs for prosthetic implants in 2006 euros. 
The two treatment strategies were evaluated with the
model by calculating the incremental cost-effectiveness
ratio. Medical interventions with an incremental cost-
effectiveness ratio less than 50,000 per QALY were
deemed to be reasonably cost-effective and this value was
used in threshold analysis. Both future costs and future
utilities, or QALY, were discounted at 3% for consistency
with current practices in cost-effectiveness analysis [8].
Results
Several different devices (Samo Duofit, Wright Medical,
Stryker, Zimmer, Hit Medica, Plus Orthopedics, Adler
Ortho) are regularly implanted at our Orthopaedics
Department. The mean costs of cemented and cementless
devices listed above were € 1146 and € 3206.44, respec-
tively (average difference, € 2060.44); the mean proce-
dure cost of revision THA was € 3249.75 (Table 1). 
With a threshold value of € 50,000, cementless THA
becomes more effective (but not more cost-effective) and
costly (but less effective) than cemented THA (Table 2).
However, neither procedure was clearly dominated by the
other (Fig. 3). 
The model is sensitive to revision rates, implant costs,
perioperative mortality and infection rates, and utility val-
ues. Analysis of 5-year follow-up data reported in the
RIPO register revealed that, with a 1.4% annual probabil-
ity of revision, cementless prostheses becomes less cost-
ly. With an incremental cost-effectiveness ratio above
€ 50,000 per QALY threshold, cemented implants do not
become cost-inefficient. If the probability of revision of
cemented THA is held constant, cementless implants do
not become less costly. In fact, even if the annual revision
rate of total cementless prostheses were 0% (i.e. no revi-
sions), the cost of each additional QALYgained by choos-
ing a cementless device is greater than $ 50,000 per
QALY, the commonly accepted threshold for cost-effec-
tive interventions. This suggests that, under our assump-
tions, cementless THA may not be more cost-effective,
regardless of its revision rates. 
The results demonstrate that the mortality associated
with cemented THA would have to exceed the rate com-
monly associated with cementless THA to become the
more cost-effective option in this patient population.
Similarly, the infection rates associated with cemented
implants would need to be higher than the rate associated
with cementless devices to be the more cost-effective
strategy. 
Discussion
Over 150 different types of prosthesis are currently used
in Italy, with significant price differences. Although rea-
sons for implant choice may include knowledge of pros-
thesis survival and function, Baxter and Bevan [3] sug-
gested that manufacturers exert a degree of influence over
surgeons’ preferences, with some orthopaedics depart-
ments being supplied by a single manufacturer. The costs
associated with a range of prosthesis prices are made
explicit in this paper.
The cost-effectiveness profile of cemented prostheses
was found to be similar to that of cementless implants for
the surgical management of hip arthritis and femoral neck
fractures in a theoretical elderly population based on
RIPO report data. The average cost difference was
€ 2060.44 in 2006 euros, without differences in QALY.
The main conclusions based on the assumptions
adopted in this study are that device cost and revision
26 J Orthopaed Traumatol (2008) 9:23–28
Table 2 Incremental analysis for cemented and cementless total hip
arthroplasty (THA). Neither strategy was clearly dominated by the
other
Parameter Cemented Cementless
THA THA
Cost (€) 3155.1 6734.10
Incremental cost (€) - 3579.00
Effectiveness 1.3 60.3
Cost-effectiveness 2353 112
Incremental cost-effectiveness ratio - 61
Fig. 3 Decision-analysis outcome.
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trates are the main costs driving total expected costs.
Based on the data used in the model, cementless prosthe-
ses appear to be less costly than cemented ones over 5
years, but not less cost-effective when an incremental cost
effectiveness ratio of less than € 50,000 per QALY was
adopted. In our theoretical 70-year-old patients, a low-
price prosthesis is generally less costly than a high-price
one, even with a very low revision rate.
One possible limitation of this study is the use of 5-year
prosthesis survival data. The survival rate of many implants
diminishes (sometimes dramatically) over time. Increases
in revision rates to levels above those assumed will
increase total expected costs. Cost rankings will also be
changed if rates of revision change relative to each other.
We did not investigate the effects of different devices
on patients’ quality of life. An interesting area for future
research would be to compare prosthesis survival and
quality of life data.
Another potential limitation of our study is that we
only considered implant cost, which is the most easily
quantifiable cost for which accurate data could be
obtained. Future models should take into account the
impact of all societal costs, including direct, indirect and
non-medical costs, on the cost-utility of THA.
We also recognize that chronological age is an imper-
fect surrogate for physiological age and activity level,
which may be more appropriate criteria on which to base
a decision-analysis model. However, most investigators
who have evaluated predictors of wear rates and implant
survival following THA have used chronological age as a
proxy for activity level [15].
It is increasingly recognized that decision-analytic
models are useful frameworks for cost-effectiveness
analysis for decision making. This is because all decisions
about health technologies inevitably face uncertainties
about the evidence base [16, 17]. 
National Institute for Clinical Excellence (NICE)
guidelines have emphasized the central role of decision
models in health technology assessment. In fact, all analy-
ses used in NICE decision making have to include proba-
bilistic sensitivity analysis [18].
The cost-effectiveness acceptability curves indicate
the probability of a given intervention being the more
(most) cost effective given the valuation of a unit of
health outcome [19].
Decision-makers increasingly seek to identify those
patients for whom a technology is most cost-effective;
probabilistic sensitivity analysis provides a way of show-
ing the additional uncertainty associated with splitting
patients into subgroups. Perhaps most importantly, proba-
bilistic sensitivity analysis can be extended to undertake
value of information analysis to inform priority-setting
and the design of future research [20].
Finally, it should be noted that the purpose of deci-
sion-analysis studies is not to influence individual clinical
decisions for individual patients, but rather to provide a
framework to help clinicians, patients, hospitals, payers,
and health policy makers to evaluate the relative cost and
relative clinical effectiveness of new healthcare technolo-
gies such as alternative bearing surfaces.
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